Notice of Clarification for PAR-11-206 - National Cooperative Drug Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders, Drug or Alcohol Addiction (UM1)

Notice Number: NOT-MH-11-017

Key Dates
Release Date: August 17, 2011

Issued by
National Institute of Mental Health (NIMH) (NIMH)
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
National Institute on Drug Abuse (NIDA)

Purpose

The purpose of this Notice is to clarify certain paragraphs in PAR-11-206 as follows:

1.   The 3rd paragraph under NIMHs objectives and interests for the NCDDG program

This program strongly encourages resource contributions (financial and in-kind), of the partners within the NCDDG (e.g., biotechnology, pharmaceutical, or disease foundations) in support of IND-directed toxicology and safety studies, Good Manufacturing Practice (GMP) synthesis, formulation,  and phase I and IIa studies.  Private sources of funding should be identified in the application.

2.  The Special Instructions/Research Strategy Page Limitations section

Other support information is not required at the time the application is submitted.  As noted in the Instructions for PHS 398, this information will be requested at an appropriate time after peer review (i.e., “just-in-time”).  The participating ICs will request and review this information prior to award.

All other aspects of the FOA remain unchanged.

Inquiries

Inquiries regarding this Notice may be directed to the Program Contacts listed in the FOA.